Notably, immunotherapy is typically administered to patients with advanced-stage TNBC, and the significance of TIL (tumor-infiltrating lymphocyte) levels and PD-L1 positivity as criteria for immunotherapy eligibility is frequently emphasized [36]. The gene discussed is CD274; the disease is neoplasm.